- Home
- FGL vs INAB Comparison
FGL vs INAB Comparison
Compare FGL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- INAB
- Stock Information
- Founded
- FGL 2021
- INAB 2016
- Country
- FGL Malaysia
- INAB United States
- Employees
- FGL N/A
- INAB N/A
- Industry
- FGL
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- FGL
- INAB Health Care
- Exchange
- FGL NYSE
- INAB Nasdaq
- Market Cap
- FGL 21.0M
- INAB 18.8M
- IPO Year
- FGL 2024
- INAB 2021
- Fundamental
- Price
- FGL $1.52
- INAB $0.18
- Analyst Decision
- FGL
- INAB Strong Buy
- Analyst Count
- FGL 0
- INAB 2
- Target Price
- FGL N/A
- INAB $3.60
- AVG Volume (30 Days)
- FGL 73.4K
- INAB 786.0K
- Earning Date
- FGL 12-17-2024
- INAB 05-08-2025
- Dividend Yield
- FGL N/A
- INAB N/A
- EPS Growth
- FGL 45.69
- INAB N/A
- EPS
- FGL 0.04
- INAB N/A
- Revenue
- FGL $23,268,519.00
- INAB N/A
- Revenue This Year
- FGL N/A
- INAB N/A
- Revenue Next Year
- FGL N/A
- INAB N/A
- P/E Ratio
- FGL $38.69
- INAB N/A
- Revenue Growth
- FGL 336.06
- INAB N/A
- 52 Week Low
- FGL $1.16
- INAB $0.13
- 52 Week High
- FGL $5.26
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- INAB 49.14
- Support Level
- FGL N/A
- INAB $0.15
- Resistance Level
- FGL N/A
- INAB $0.18
- Average True Range (ATR)
- FGL 0.00
- INAB 0.02
- MACD
- FGL 0.00
- INAB 0.01
- Stochastic Oscillator
- FGL 0.00
- INAB 93.22
About FGL FOUNDER GROUP LTD
Founder Group Ltd acts as an end-to-end Engineering, Procurement, Construction, and Commissioning solutions provider for solar PV facilities in Malaysia. The segments of the company are large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects of the company are utility-scale solar PV power plants with installed generating capacity of 1 MWac or more, and C&I projects of the company are smaller-scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their consumption at factories, warehouses, and commercial stores. The company derives its revenue from Malaysia.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.